Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Achieve Life Sciences (ACHV) Tops Q4 EPS by 9c
March 14, 2019 4:17 PM EDTAchieve Life Sciences (NASDAQ: ACHV) reported Q4 EPS of ($0.55), $0.09 better than the analyst estimate of ($0.64).
Recent highlights:
Completion of enrollment in 254-subject Phase 2b ORCA-1 trial of cytisinicline in U.S. smokersPresented final data from cytisinicline Phase 1/2 multi-dose,... More